東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Regulation of genome editing in huma...

Dederer, Hans-Georg.

Linked to FindBook

Google Book

Amazon

博客來

Regulation of genome editing in human iPS cells = a comparative legal analysis of national regulatory frameworks for IPSC-based cell/gene therapies /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Regulation of genome editing in human iPS cells/ edited by Hans-Georg Dederer, Gregor Frenken.
Reminder of title:	a comparative legal analysis of national regulatory frameworks for IPSC-based cell/gene therapies /
other author:	Dederer, Hans-Georg.
Published:	Cham :Springer International Publishing : : 2022.,
Description:	x, 334 p. :ill., digital ;24 cm.
[NT 15003449]:	Introduction -- Biological Aspects of Genome Editing in iPS Cells -- Ethical Aspects in the Context of Genome Editing -- Regulation of Genome Editing in iPS Cells: Germany -- Regulation of Genome Editing in iPS Cells: France -- Regulation of Genome Editing in iPS Cells: Switzerland -- Regulation of Genome Editing in iPS Cells: United States -- Regulation of Genome Editing in iPS Cells: Japan -- Regulation of Genome Editing in iPS Cells: Republic of Korea -- Comparative Analysis.
Contained By:	Springer Nature eBook
Subject:	Gene editing - Law and legislation. -
Online resource:	https://doi.org/10.1007/978-3-030-93023-3
ISBN:	9783030930233

Regulation of genome editing in human iPS cells = a comparative legal analysis of national regulatory frameworks for IPSC-based cell/gene therapies /
Regulation of genome editing in human iPS cellsa comparative legal analysis of national regulatory frameworks for IPSC-based cell/gene therapies /[electronic resource] :edited by Hans-Georg Dederer, Gregor Frenken. - Cham :Springer International Publishing :2022. - x, 334 p. :ill., digital ;24 cm.

Introduction -- Biological Aspects of Genome Editing in iPS Cells -- Ethical Aspects in the Context of Genome Editing -- Regulation of Genome Editing in iPS Cells: Germany -- Regulation of Genome Editing in iPS Cells: France -- Regulation of Genome Editing in iPS Cells: Switzerland -- Regulation of Genome Editing in iPS Cells: United States -- Regulation of Genome Editing in iPS Cells: Japan -- Regulation of Genome Editing in iPS Cells: Republic of Korea -- Comparative Analysis.

The book provides a concise overview of currently applicable regulatory frameworks of states which are among the world leaders in research and development (R&D) of cell and gene therapies. Developments in genome editing are expected to lead to new possibilities for the treatment of hereditary diseases in humans. The treatment of such often severe but hitherto uncurable diseases can be based on genome-edited induced pluripotent stem cells (iPS cells) Such treatments constitute combined cell/gene therapies. These therapies need to be governed by a regulatory framework which ensures quality, safety, and efficacy of the relevant therapeutic products. On the other hand, such regulations may retard product approval and impede R&D. Accordingly, national regulations for therapies based on genome-edited iPS cells are an important and, as the case may be, decisive factor for both researchers and industry regarding their decision where to locate their R&D activities. Therefore, regulatory frameworks impact significantly on the competitiveness of states and their economies. This is why a comparative analysis of laws and regulations of different countries matters. Such a comparative legal analysis provides an important insight into regulatory concepts which, in turn, may inspire adjustments of, or amendments to, domestic legal regimes. For this purpose, experts present country reports on France, Germany, Japan, South Korea, Switzerland, and the USA. The reports on France and Germany also refer to the parameters and implications arising from pertinent EU law. This contributed volume is aimed at researchers, but also at, e.g., legal scholars, lawmakers, regulators, and political decision makers.

ISBN: 9783030930233

Standard No.: 10.1007/978-3-030-93023-3doiSubjects--Topical Terms:

3599265
Gene editing
--Law and legislation.

LC Class. No.: K3611.G46

Dewey Class. No.: 344.04196

Regulation of genome editing in human iPS cells = a comparative legal analysis of national regulatory frameworks for IPSC-based cell/gene therapies /
LDR:03335nmm a2200349 a 4500 001 2300603
003 DE-He213
005 20220523120210.0
006 m d
007 cr nn 008maaau
008 230324s2022 sz s 0 eng d
020 $a 9783030930233 $q (electronic bk.)
020 $a 9783030930226 $q (paper)
024 7 $a 10.1007/978-3-030-93023-3 $2 doi
035 $a 978-3-030-93023-3
040 $a GP $c GP
041 0 $a eng
050 4 $a K3611.G46
072 7 $a LB $2 bicssc
072 7 $a LAM $2 bicssc
072 7 $a LAW051000 $2 bisacsh
072 7 $a LB $2 thema
072 7 $a LAM $2 thema
082 0 4 $a 344.04196 $2 23
090 $a K3611.G46 $b R344 2022
245 0 0 $a Regulation of genome editing in human iPS cells $h [electronic resource] : $b a comparative legal analysis of national regulatory frameworks for IPSC-based cell/gene therapies / $c edited by Hans-Georg Dederer, Gregor Frenken.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2022.
300 $a x, 334 p. : $b ill., digital ; $c 24 cm.
505 0 $a Introduction -- Biological Aspects of Genome Editing in iPS Cells -- Ethical Aspects in the Context of Genome Editing -- Regulation of Genome Editing in iPS Cells: Germany -- Regulation of Genome Editing in iPS Cells: France -- Regulation of Genome Editing in iPS Cells: Switzerland -- Regulation of Genome Editing in iPS Cells: United States -- Regulation of Genome Editing in iPS Cells: Japan -- Regulation of Genome Editing in iPS Cells: Republic of Korea -- Comparative Analysis.
520 $a The book provides a concise overview of currently applicable regulatory frameworks of states which are among the world leaders in research and development (R&D) of cell and gene therapies. Developments in genome editing are expected to lead to new possibilities for the treatment of hereditary diseases in humans. The treatment of such often severe but hitherto uncurable diseases can be based on genome-edited induced pluripotent stem cells (iPS cells) Such treatments constitute combined cell/gene therapies. These therapies need to be governed by a regulatory framework which ensures quality, safety, and efficacy of the relevant therapeutic products. On the other hand, such regulations may retard product approval and impede R&D. Accordingly, national regulations for therapies based on genome-edited iPS cells are an important and, as the case may be, decisive factor for both researchers and industry regarding their decision where to locate their R&D activities. Therefore, regulatory frameworks impact significantly on the competitiveness of states and their economies. This is why a comparative analysis of laws and regulations of different countries matters. Such a comparative legal analysis provides an important insight into regulatory concepts which, in turn, may inspire adjustments of, or amendments to, domestic legal regimes. For this purpose, experts present country reports on France, Germany, Japan, South Korea, Switzerland, and the USA. The reports on France and Germany also refer to the parameters and implications arising from pertinent EU law. This contributed volume is aimed at researchers, but also at, e.g., legal scholars, lawmakers, regulators, and political decision makers.
650 0 $a Gene editing $x Law and legislation. $3 3599265
650 1 4 $a Private International Law, International and Foreign Law, Comparative Law. $3 3538685
650 2 4 $a European Law. $3 1566626
650 2 4 $a Medical Genetics. $3 3531302
700 1 $a Dederer, Hans-Georg. $3 3503027
700 1 $a Frenken, Gregor. $3 3599264
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-3-030-93023-3
950 $a Law and Criminology (SpringerNature-41177)